New England Research & Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.66M | Buy |
21,070
+10,000
| +90% | +$1.32M | 1.04% | 29 |
|
|
2026
Q1 | $1.54M | Sell |
11,070
-630
| -5% | -$88.2K | 0.65% | 53 |
|
|
2025
Q4 | $1.44M | Buy |
+11,700
| New | +$1.42M | 0.63% | 50 |
|
|
2024
Q4 | – | Sell |
-4,800
| Closed | -$402K | – | 163 |
|
|
2024
Q3 | $402K | Sell |
4,800
-587
| -11% | -$44.8K | 0.19% | 123 |
|
|
2024
Q2 | $370K | Sell |
5,387
-11,438
| -68% | -$763K | 0.18% | 141 |
|
|
2024
Q1 | $1.23M | Buy |
16,825
+11,300
| +205% | +$869K | 0.6% | 56 |
|
|
2023
Q4 | $448K | Buy |
+5,525
| New | +$430K | 0.24% | 116 |
|
|
2022
Q3 | – | Sell |
-12,350
| Closed | -$763K | – | 172 |
|
|
2022
Q2 | $763K | Buy |
+12,350
| New | +$765K | 0.44% | 86 |
|
|
2020
Q3 | – | Sell |
-5,410
| Closed | -$416K | – | 143 |
|
|
2020
Q2 | $416K | Buy |
5,410
+2,250
| +71% | +$172K | 0.3% | 102 |
|
|
2020
Q1 | $236K | Sell |
3,160
-17,370
| -85% | -$1.2M | 0.2% | 121 |
|
|
2019
Q4 | $1.33M | Buy |
20,530
+11,150
| +119% | +$726K | 0.89% | 32 |
|
|
2019
Q3 | $595K | Sell |
9,380
-50
| -0.5% | -$3.27K | 0.43% | 85 |
|
|
2019
Q2 | $637K | Sell |
9,430
-475
| -5% | -$31.2K | 0.43% | 88 |
|
|
2019
Q1 | $644K | Sell |
9,905
-450
| -4% | -$29.9K | 0.44% | 81 |
|
|
2018
Q4 | $648K | Sell |
10,355
-60
| -0.6% | -$4.19K | 0.51% | 74 |
|
|
2018
Q3 | $804K | Hold |
10,415
| – | – | 0.52% | 71 |
|
|
2018
Q2 | $738K | Sell |
10,415
-13,840
| -57% | -$977K | 0.49% | 78 |
|
|
2018
Q1 | $1.83M | Buy |
24,255
+5,550
| +30% | +$441K | 1.23% | 15 |
|
|
2017
Q4 | $1.34M | Buy |
18,705
+215
| +1% | +$16.3K | 0.96% | 35 |
|
|
2017
Q3 | $1.5M | Buy |
18,490
+2,050
| +12% | +$157K | 1.1% | 25 |
|
|
2017
Q2 | $1.16M | Sell |
16,440
-2,325
| -12% | -$155K | 0.86% | 37 |
|
|
2017
Q1 | $1.27M | Sell |
18,765
-50
| -0.3% | -$3.52K | 0.98% | 27 |
|
|
2016
Q4 | $1.35M | Buy |
18,815
+9,925
| +112% | +$738K | 1.06% | 21 |
|
|
2016
Q3 | $703K | Buy |
8,890
+5,625
| +172% | +$457K | 0.59% | 57 |
|
|
2016
Q2 | $272K | Buy |
3,265
+175
| +6% | +$15.5K | 0.23% | 134 |
|
|
2016
Q1 | $284K | Sell |
3,090
-6,390
| -67% | -$576K | 0.24% | 124 |
|
|
2015
Q4 | $959K | Buy |
9,480
+730
| +8% | +$76K | 0.83% | 34 |
|
|
2015
Q3 | $859K | Buy |
8,750
+900
| +11% | +$100K | 0.82% | 36 |
|
|
2015
Q2 | $919K | Sell |
7,850
-1,900
| -19% | -$208K | 0.75% | 44 |
|
|
2015
Q1 | $957K | Hold |
9,750
| – | – | 0.82% | 38 |
|
|
2014
Q4 | $919K | Sell |
9,750
-50
| -0.5% | -$5.17K | 0.79% | 37 |
|
|
2014
Q3 | $1.04M | Sell |
9,800
-250
| -2% | -$24.5K | 0.91% | 29 |
|
|
2014
Q2 | $833K | Buy |
10,050
+6,050
| +151% | +$471K | 0.75% | 52 |
|
|
2014
Q1 | $283K | Buy |
+4,000
| New | +$314K | 0.26% | 127 |
|
Other funds holding GILD
New England Research & Management's GILD Position: Q2 2026 in Review
New England Research & Management increased its Gilead Sciences (GILD) stake by 90% in Q2 2026, buying an estimated $1.32M and bringing the position to 21,070 shares worth $2.66M. The position accounts for 1.04% of the portfolio, ranked #29.
New England Research & Management first reported a position in GILD in Q1 2014 and has held it in 34 quarters since. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- New England Research & Management held 21,070 shares of Gilead Sciences worth $2.66M as of Q2 2026.
- New England Research & Management bought 10,000 Gilead Sciences shares in Q2 2026, an estimated $1.32M.
- Gilead Sciences made up 1.04% of New England Research & Management's portfolio in Q2 2026, its #29 holding.
- New England Research & Management first reported a position in Gilead Sciences in Q1 2014 and has held it in 34 quarters since.
- 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.